Scarica l'app Stockscreener
38.91
2.26%
-0.90
Dopo l'orario di chiusura:
39.23
0.32
+0.82%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché EXEL Giù?
Forum
Previsione
Precedente Chiudi:
$39.81
Aprire:
$39.7
Volume 24 ore:
2.01M
Relative Volume:
0.63
Capitalizzazione di mercato:
$10.47B
Reddito:
$2.17B
Utile/perdita netta:
$521.27M
Rapporto P/E:
21.98
EPS:
1.77
Flusso di cassa netto:
$633.79M
1 W Prestazione:
-3.78%
1M Prestazione:
+0.72%
6M Prestazione:
+3.15%
1 anno Prestazione:
+48.06%
Intervallo 1D:
$38.56
$39.99
Intervallo di 1 settimana:
$38.56
$40.66
Portata 52W:
$25.17
$49.62
Exelixis Inc Stock (EXEL) Company Profile
Nome
Exelixis Inc
Settore
Industria
Telefono
(650) 837-7000
Indirizzo
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
Confronta EXEL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EXEL
Exelixis Inc
|
38.91 | 10.72B | 2.17B | 521.27M | 633.79M | 1.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
376.62 | 97.36B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
576.98 | 60.19B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.37 | 59.56B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
729.76 | 44.94B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
329.84 | 36.14B | 3.81B | -644.79M | -669.77M | -6.24 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-19 | Ripresa | Barclays | Equal Weight |
| 2025-09-17 | Ripresa | Barclays | Equal Weight |
| 2025-09-17 | Iniziato | Goldman | Buy |
| 2025-07-08 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-06-24 | Aggiornamento | Stephens | Equal-Weight → Overweight |
| 2025-02-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-01-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-01-24 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-12-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-17 | Downgrade | BofA Securities | Buy → Neutral |
| 2024-10-16 | Reiterato | RBC Capital Mkts | Outperform |
| 2024-09-19 | Iniziato | UBS | Neutral |
| 2024-04-11 | Downgrade | Barclays | Overweight → Equal Weight |
| 2023-12-19 | Iniziato | BTIG Research | Buy |
| 2023-12-15 | Iniziato | Citigroup | Buy |
| 2023-09-26 | Iniziato | H.C. Wainwright | Buy |
| 2023-08-22 | Reiterato | Oppenheimer | Outperform |
| 2023-08-08 | Iniziato | SVB Securities | Market Perform |
| 2023-07-11 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-05-10 | Ripresa | Piper Sandler | Overweight |
| 2023-03-09 | Iniziato | Wells Fargo | Overweight |
| 2023-01-26 | Iniziato | Credit Suisse | Outperform |
| 2022-10-18 | Iniziato | JMP Securities | Mkt Outperform |
| 2022-06-24 | Iniziato | BMO Capital Markets | Outperform |
| 2021-11-19 | Iniziato | Piper Sandler | Overweight |
| 2021-11-03 | Ripresa | Jefferies | Buy |
| 2021-10-07 | Iniziato | Jefferies | Buy |
| 2021-08-06 | Reiterato | H.C. Wainwright | Buy |
| 2021-06-15 | Iniziato | H.C. Wainwright | Buy |
| 2021-05-18 | Ripresa | Goldman | Sell |
| 2021-03-31 | Iniziato | Credit Suisse | Outperform |
| 2021-03-12 | Iniziato | Wolfe Research | Outperform |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-01-13 | Iniziato | SunTrust | Buy |
| 2019-11-13 | Iniziato | BofA/Merrill | Buy |
| 2019-03-18 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2018-09-17 | Iniziato | Goldman | Neutral |
| 2018-09-10 | Iniziato | Morgan Stanley | Underweight |
| 2018-05-11 | Reiterato | Needham | Buy |
| 2017-10-17 | Reiterato | Needham | Buy |
| 2017-10-17 | Reiterato | RBC Capital Mkts | Outperform |
| 2017-10-16 | Reiterato | SunTrust | Buy |
| 2017-09-22 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Outperform |
| 2017-09-12 | Reiterato | Needham | Buy |
| 2017-07-14 | Iniziato | SunTrust | Buy |
| 2017-03-31 | Iniziato | Needham | Buy |
| 2017-03-16 | Iniziato | Oppenheimer | Perform |
| 2017-02-28 | Downgrade | Stifel | Buy → Hold |
| 2016-11-03 | Iniziato | Deutsche Bank | Buy |
| 2016-10-10 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2016-09-15 | Reiterato | Stifel | Buy |
Mostra tutto
Exelixis Inc Borsa (EXEL) Ultime notizie
Exelixis at Bernstein Forum: Oncology Focus and Strategic Growth By Investing.com - Investing.com Canada
Exelixis (NASDAQ:EXEL) Now Covered by Barclays - MarketBeat
The Bull Case For Exelixis (EXEL) Could Change Following Expanded Collaboration With Adagene’s SAFEbody Platform - simplywall.st
Exelixis Gains Analyst Confidence as Cancer Studies Advances - MSN
Exelixis (NASDAQ:EXEL) Now Covered by The Goldman Sachs Group - MarketBeat
Exelixis (EXEL) Tumbles 16.8% as Q2 Earnings Disappoint - MSN
Published on: 2025-09-20 12:21:38 - خودرو بانک
Aug Fed Impact: Is Gold Royalty Corp a strong candidate for buy and holdEarnings Miss & Safe Entry Point Identification - khodrobank.com
Exelixis (EXEL) Has a New Rating from Barclays - The Globe and Mail
Market Pulse: Does Exelixis Inc have a competitive edgeRisk Management & Consistent Growth Stock Picks - khodrobank.com
Exelixis Inc (NASDAQ:EXEL) Initiated By Goldman Sachs - FXDailyReport.Com
Exelixis Trying To Close In On Key Technical Benchmark - MSN
Could Access to SAFEbody Technology Shift Exelixis (EXEL) Pipeline Strategy in Oncology? - Yahoo Finance
Exelixis (NASDAQ:EXEL) Coverage Initiated by Analysts at The Goldman Sachs Group - Defense World
Morgan Stanley Issues Positive Forecast for Exelixis (NASDAQ:EXEL) Stock Price - Defense World
Valuation Update: What analysts say about Exelixis Inc. stockJuly 2025 Intraday Action & Weekly Sector Rotation Insights - خودرو بانک
Lingohr Asset Management GmbH Sells 93,560 Shares of Exelixis, Inc. $EXEL - MarketBeat
Belpointe Asset Management LLC Purchases New Holdings in Exelixis, Inc. $EXEL - MarketBeat
Exelixis (NASDAQ:EXEL) Stock Rating Lowered by Wall Street Zen - MarketBeat
Analysts Set Exelixis, Inc. (NASDAQ:EXEL) Target Price at $44.06 - MarketBeat
Goldman Sachs Initiates Coverage of Exelixis (EXEL) with Buy Recommendation - Nasdaq
Goldman Sachs Recommends Buy on Exelixis (EXEL) with Focus on Za - GuruFocus
Exelixis earns new Buy at Goldman Sachs (EXEL:NASDAQ) - Seeking Alpha
Goldman Sachs Initiates Coverage on Exelixis (EXEL) with a 'Buy' Rating | EXEL Stock News - GuruFocus
Aug Macro: Can Atlassian Corporation generate free cash flowQuarterly Performance Summary & Real-Time Stock Entry Alerts - khodrobank.com
Barclays Initiates Coverage on Exelixis (EXEL) with Equal-Weight Rating | EXEL Stock News - GuruFocus
Barclays Initiates Coverage of Exelixis (EXEL) with Equal-Weight Recommendation - Nasdaq
32,270 Shares in Exelixis, Inc. $EXEL Acquired by Lifestyle Asset Management Inc. - MarketBeat
Livforsakringsbolaget Skandia Omsesidigt Purchases Shares of 111,158 Exelixis, Inc. $EXEL - MarketBeat
Ellsworth Advisors LLC Invests $3.59 Million in Exelixis, Inc. $EXEL - MarketBeat
Exelixis, Inc. $EXEL Shares Sold by Acadian Asset Management LLC - MarketBeat
Exelixis Announces New Executive VP for R&D - MSN
Exelixis, Inc. $EXEL Shares Purchased by Voya Investment Management LLC - MarketBeat
Modern Wealth Management LLC Acquires New Stake in Exelixis, Inc. $EXEL - MarketBeat
Fred Alger Management LLC Has $779,000 Position in Exelixis, Inc. $EXEL - MarketBeat
Fortis Capital Advisors LLC Takes $572,000 Position in Exelixis, Inc. $EXEL - MarketBeat
Bearish Setup: How do insiders feel about Exelixis IncJuly 2025 Intraday Action & Reliable Breakout Stock Forecasts - خودرو بانک
CEO Change: Is Exelixis Inc being accumulated by smart moneyMarket Growth Report & AI Driven Stock Price Forecasts - خودرو بانک
Will earnings trigger a reversal in Exelixis Inc.2025 Key Lessons & Fast Exit and Entry Trade Guides - newser.com
Exelixis Inc Azioni (EXEL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.30%
2.51%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):